By Nikki Kean
There is new hope in the treatment of progressive multiple sclerosis (MS). Promising results of a phase 2 trial showed that ibudilast decreased progression of brain atrophy in patients with progressive MS by 48% compared with those taking placebo (N Engl J Med 2018;379[9]:846-855).
The two-year placebo-controlled trial, called the SPRINT-MS study, was conducted at 28 sites in the United States and included 255 patients. The study aimed to determine the safety, tolerability and
SEPTEMBER 21, 2018